| INTRODUCTION
The development of antibody-mediated rejection (AMR) persists as a major issue limiting long-term patient and allograft survival. induce outside-in signaling pathways eliciting cytoskeletal remodeling, proliferation, and migration. 10 HLA I Ab signaling also triggers rapid mobilization of Weibel-Palade bodies (WPBs), induction of P-selectin, and recruitment of leukocytes to the activated endothelium. [11] [12] [13] Mechanistic target of rapamycin (mTOR) can promote endothelial cell (EC)-leukocyte interactions, suggesting immunotherapy with rapalogs may be beneficial in preventing graft injury mediated by AMR. [14] [15] [16] [17] [18] mTOR inhibitors are widely used for cancer and atherosclerosis 19, 20 ; however, they are also used as an immunosuppressive agent to prevent rejection of solid organ transplants.
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A number of studies have demonstrated efficacy of mTOR inhibitors for attenuating cardiac TAV, 22 ,23 yet the underlying mechanism remains unclear.
Here, we investigated the role of mTOR in monocyte recruitment to HLA I Ab-activated ECs. Our data demonstrate mTOR signaling induces intracellular adhesion molecule 1 (ICAM-1) clustering on the EC surface, which stabilizes monocyte firm adhesion, critical for transendothelial migration under conditions of physiological shear flow.
Accordingly, mTOR inhibition in a murine model suppressed monocyte infiltration into allografts undergoing AMR with a concomitant decrease in capillary EC phosphorylation of downstream proteins.
Taken together, these studies provide much needed mechanistic insight into the function of clinical mTOR inhibitors and their potential use in treating AMR.
| MATERIALS AND METHODS

| Reagents
Pan-HLA class I mAb recognizing distinct monomorphic epitopes 
Everolimus (RAD001 [RAD]) was from Novartis Pharma AG
(Switzerland). siRNAs were designed as previously described 15 and obtained from Dharmacon/GE Healthcare Life Sciences (Lafayette, CO). Bapta-AM, UO126, Ro-31-7549, Y27632, and rabbit pAb to mTOR, Raptor, and Rictor were from Calbiochem/ EMD Millipore (Billerica, MA Rat anti-mouse Mac2 was from Cedarlane (Hornby, Ontario, Canada). Before use, all Ab were titered to determine optimal working concentrations and their specificity was confirmed by using appropriate positive and negative controls.
| Human cells
Use of all human cells was approved by the UCLA Institutional Review
Board (IRB#10-001689; IRB#00-01-023). Primary ECs were isolated from aortic rings of deceased donor hearts or were obtained from Clonetics (EC5555; San Diego, CA) and cultured as previously described. 16, 28, 29 The monocytic cell line Mono Mac 6 (MM6; a gift from Dr Loems Ziegler-Heitbrock, Germany) was cultured as described.
11
Primary human monocytes were enriched from the peripheral blood of multiple healthy volunteers by using Ficoll-Paque (GE Healthcare) density centrifugation, followed by MACS pan-monocyte negative selection (Miltenyi) as we previously described 12 at an average final purity of 89.8% based on positive CD14 staining as determined by flow cytometry using an LSRFortessa (BD Biosciences). Experiments were performed with early-passage ECs from 2 or 3 different donors.
Monocyte Fc interactions with ECs were inhibited by incubation with human IgG. 
| Monocyte static and shear-based adhesion assays
Adherence of monocytes to ECs under static conditions was measured as described. 11, 12 Briefly, ECs were pretreated with 30 μg/mL of 10 nmol/L Rapa or 30 nmol/L RAD ( Figure S1 ) or 100 nmol/L siRNA (siRNA efficiency and specificity are shown in Figure S2 ), then stimu- 
| Flow cytometry and ELISAs
Cell surface expression of P-selectin was measured on adherent
ECs by the use of a cell-based ELISA. 11, 30 Cell surface expression of 
| Murine heterotopic heart transplantation
| Statistical analysis
Differences between groups were determined using 1-or 2-way ANOVA using Prism 5 (GraphPad). P-values of <.05 were considered statistically significant.
| RESULTS
| mTOR inhibition in ECs significantly reduces HLA I Ab-induced monocyte recruitment
We characterized the capacity of 2 different US Food and Drug Administration-approved pharmacologic mTOR inhibitors, sirolimus or PBMC-derived monocytes (right) adherent to treated ECs over untreated ECs ± SEM from 5 independent experiments. ****P < .0001, ns=not significant comparing treated ECs with untreated ECs by 2-way ANOVA with Tukey's multiple-comparisons test. B, ECs were pretreated with rapamycin (Rapa), RAD001 (RAD), or no inhibitor for 24 hours, or BAPTA-AM for 30 minutes before monocytes were allowed to adhere. Shown are fold changes in mean number of MM6 cells (left) or PBMCderived monocytes (right) adherent to treated ECs over untreated control ECs (dotted line) ± SEM from 5 independent experiments. *P < .05, **P < .01, ***P < .001 for ECs given the indicated inhibitor to ECs given no inhibitor by 2-way ANOVA with Tukey's multiple-comparisons test. C, Representative images showing CFSE-labeled MM6 cells adherent to the endothelial monolayer following indicated treatment. Scale bars = 100 μm. D, ECs were pretreated with no inhibitor, Rapa, or RAD for 2 hours (targets mechanistic target of rapamycin [mTORC]1 or 2, respectively) or BAPTA-AM for 30 minutes before MM6 cells were allowed to adhere. Shown are fold changes in mean numbers of MM6 cells adherent to treated ECs over untreated control ECs (dotted line) ± SEM from 5 independent experiments. *P < .05 for ECs given the indicated inhibitor to ECs given no inhibitor by 2-way ANOVA with Tukey's multiple-comparisons test. E, ECs were pretreated with control siRNA or siRNA directed against mTOR, Raptor (mTORC1), or Rictor (mTORC2) before MM6 cells were allowed to adhere. Shown are fold changes in numbers of MM6 cells adherent to treated ECs over untreated control ECs (dotted line) ± SEM from 5 independent experiments. **P < .01, ***P < .001 for ECs given the indicated siRNA to ECs given no siRNA by 2-way ANOVA with Tukey's multiple-comparisons test mTOR can complex with regulatory-associated protein of mTOR (Raptor) to form mTOR complex 1 (mTORC1) or rapamycin-insensitive companion of mTOR (Rictor) to form mTOR complex 2 (mTORC2), with differing downstream effects. We used 2 complementary approaches to investigate mTOR complex involvement in HLA I Ab-mediated monocyte recruitment to ECs ( Figure 1D ,E). First, we treated ECs with short-term Rapa or RAD for 2 hours before stimulation with HLA I Ab to determine the contribution of mTORC1 protein complexes to monocyte recruitment, as rapalogs require more than 6 hours to inhibit mTORC2 formation but inhibit mTORC1 formation rapidly. 15, 16 Adherence of MM6 cells was significantly attenuated with 2-hour Rapa or RAD pretreatment of ECs ( Figure 1D ) although not as completely as 24-hour pretreatment to block formation of both complexes 
| In vivo blockade of mTOR ameliorates MHC class I Ab-mediated AMR
We then tested the requirement for mTOR in monocyte recruitment to HLA I Ab-activated endothelium in vivo using a clinically relevant murine model. 
| mTOR regulates ICAM-1-induced firm adhesion of monocytes to HLA I Ab-stimulated ECs
We next sought to characterize the mechanism by which mTOR Rapa is known to directly inhibit protein synthesis 35 ; however, we did not find any significant changes in the basal surface expression levels of key molecules in the leukocyte adhesion cascade, 36 including ICAM-1 ( Figure 3C ), E-selectin, or VCAM-1 ( Figure S4B ) on activating
ECs with HLA I Ab, with or without Rapa pretreatment.
Because expression levels of adhesion molecules were not altered, we chose to investigate the effects of mTOR inhibition on the adhesive function of the endothelium under physiological shear flow conditions ( Figure 3D , Videos S1-S3). When we perfused MM6 cells over HLA I Ab-activated endothelial monolayers, we observed increased adhesion compared with untreated control ECs ( Figure 3D , left, and Videos S1,S2). However, the percentage of firmly adherent MM6 cells was significantly decreased when ECs were pretreated with Rapa compared with no inhibitor treatment ( Figure 3D , left, and Videos S2,S3).
The capacity of Rapa to inhibit firm adhesion of MM6 cells was com- 
| mTOR inhibition in HLA I Ab-stimulated EC impairs ICAM-1 clustering
ICAM-1 clusters at the apical membrane of ECs and promotes leukocyte firm adhesion by forming a "ring" or "cup" around the adhered leukocyte. [36] [37] [38] As this clustering event is essential for firm adherence, kg daily was initiated 1 day posttransplantation. B, Grafts were procured at day 30 posttransplantation and evaluated for microvascular abnormalities by staining with hematoxylin and eosin, as well as intravascular activated mononuclear cells and/or complement deposition by immunohistochemical staining for MAC2 or C4d, respectively. Arrowheads in top row indicate prominent nuclei of cells in distended capillaries of anti-MHC I-treated animals that was not seen in the anti-MHC I group treated with Rapa or either group that received control mIgG mAb where arrowheads indicate flat, thin nuclei in collapsed capillaries. Scale bars = 50 μm. C, Shown are mean scores ± SEM for n ≥ 6 per group with each dot representing 1 animal. *P < .05; **P < .01; ***P < .001; ****P < .0001 by 2-way ANOVA with Tukey's multiple-comparisons test Figure 6A,B) ; however, we saw no effect on inhibition F I G U R E 5 Ezrin/radixin/moesin (ERM) phosphorylation is impaired by mechanistic target of rapamycin (mTOR) inhibition in HLA class I Ab-activated endothelial cells (ECs). ECs were pretreated with rapamycin (Rapa) or RAD001 (RAD) for 24 hours and stimulated with HLA I Ab (anti-HLA I; clone W6/32) for 10 minutes. A, Cells were lysed and proteins were separated by SDS-PAGE followed by immunoblotting to detect phosphorylated Ezr Thr456 /Rad Thr564 /Moes Thr558 (p-ERM) as well as vinculin to confirm equal loading of proteins and were quantified by densitometry scan analysis by using ImageJ. Results are expressed as the mean fold increase in p-ERM expression over untreated ECs ± SEM over 3 independent experiments. B, ECs were transfected with either control siRNA or siRNA directed against mTOR, Raptor (MTORC1), or Rictor (MTORC2) before treatment with anti-HLA I for 10 minutes. Cells were lysed after 48 hours and proteins were separated by SDS-PAGE followed by immunoblotting to detect p-ERM as well as anti-vinculin mAb to confirm equal loading of proteins and were quantified by densitometry scan analysis by using ImageJ. Results are expressed as the mean fold increase in p-ERM expression over untreated ECs ± SEM over 3 independent experiments. C, ECs were pretreated with Rapa or RAD for 24 hours and stimulated with anti-HLA I for 10 minutes. Cells lysates were immunoprecipitated (IP) with anti-ICAM-1 followed by immunoblotting to detect p-ERM as above. Results are expressed as the mean fold increase in p-ERM expression over untreated ECs ± SEM over 3 independent experiments. **P < .01; ****P < .0001 by 2-way ANOVA with Tukey's multiple-comparisons test of the mTOR pathway, with no changes in Akt 473 or p70S6K
| HLA I Ab-induced ERM phosphorylation is impaired by mTOR inhibition in ECs
(Figure S6). Pretreatment of ECs with pharmacological inhibitors
targeting Rho or ROCK significantly reduced adherence of monocytes to HLA I Ab-activated endothelium ( Figure S7 ). However, PKC inhibition had no effect on levels of phosphorylated target proteins or monocyte adherence ( Figure 6A , B, S6, and S7). Collectively, these data indicate that following HLA class I engagement by Ab, mTOR signals through the Rho pathway via ROCK to mediate ERM phosphorylation and subsequent monocyte adhesion to ECs. Leukocyte adhesion to the activated endothelium is tightly regulated by the selectin family of molecules. E-and P-selectin mediate the initial steps of monocyte tethering and adhesion to ECs, whereas ICAM-1 and VCAM-1 are needed for firm adhesion. 36 Because previous studies showed crosslinking HLA I on ECs by Ab induces P-selectin expression and monocyte capture, 11, 13 we reasoned that mTOR inhibition might affect this process. However, while Rapa inhibits VCAM-1 expression by TNFα-activated ECs, 45 neither Rapa nor RAD altered protein expression of VCAM-1, E-selectin, P-selectin, or ICAM-1 in HLA I Ab-activated ECs. Instead, mTOR inhibition abrogated ICAM-1 translocation to the site of leukocytes, which is consistent with previous studies. and treated with daily Rapa before immunohistochemical analysis of proteins involved in MHC I-induced cell survival/proliferation pathways. A, Grafts were procured at day 30 posttransplantation and evaluated for p-ERK, p-AKT, p-S6K, and/or p-ERM expression by immunohistochemical staining. All phosphorylated proteins are visible in cardiac vessels and endocardium (dark brown) in cardiac vessels and endocardium. Scale bars = 50 μm. C, Shown are mean scores ± SEM for n ≥ 6 per group with each dot representing 1 animal. *P < .05; **P < .01; ***P < .001; ****P < .0001 by 2-way ANOVA with Tukey's multiple-comparisons test (PIP 2 ) to inositol 1, 4, 5 -triphosphate (IP 3 ), 50 a requirement for activation of the ERM proteins. 51 Notably, RhoA plays an important role in monocyte adhesion to TNFα-activated human ECs, 38 and EC activation can lead to Rho-induced ERM phosphorylation.
|
37, 38
Here, we show that Rho is required for HLA I Ab-mediated phosphorylation of ERM. While Rho or Rho kinase inhibition prevented HLA I-induced ERM phosphorylation, it had no effect on HLA I
Ab-induced activation of the mTOR signaling, indicating mTOR is upstream of Rho. RhoA activity has been reported to be dependent on both mTORC1 and mTORC2, which mediate its expression and GTPase activity, respectively. TAV in cardiac recipients [21] [22] [23] ; therefore, targeting the mTOR pathway may alleviate vascular injury in the setting of AMR by reducing microvascular inflammation. We did not characterize the effect of Rapa on the thrombin inflammatory pathway that can also mediate monocyte recruitment during AMR via PKC signaling. 54 Given the observation of thrombotic microangiopathy in early kidney AMR 55 and the role of thrombin in amplifying the production of monocyte chemoattractant protein-1, 56 it would be important to determine whether Rapa therapy attenuates PKC signaling. It is known that mTORC2 phosphorylates PKCs, as it phosphorylates AKT. Based on previously reported data, [57] [58] [59] we would argue that long-term treatment with Rapa is likely to affect PKCs. However, it remains to be tested in primary human ECs. In addition, mTOR's regulation of monocyte-EC adhesive interactions is likely important in other immune and inflammatory disorders including atherosclerosis and cancer. As such, the signaling pathways we identified here may be broadly applicable to other inflammatory diseases. 
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